The impact of rotigotine on cardiovascular autonomic function in early parkinson's disease

Camilla Rocchi, Mariangela Pierantozzi, Valerio Pisani, Girolama Alessandra Marfia, Alessandra Di Giorgio, Paolo Stanzione, Giorgio Bernardi, Alessandro Stefani

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Dysautonomia can occur in early stages of Parkinson's disease (PD) influencing tolerance to dopaminergic therapies. Rotigotine, a non-ergot dopamine agonist, has recently been developed as an effective alternative antiparkinsonian drug, but its influence on the autonomic nervous system was not investigated. Twenty subjects out of 34 consecutive de novo PD patients were submitted to full assessment of cardiovascular autonomic function before and after reaching a stable rotigotine regimen [6 mg/24 h (n = 3) or 8 mg/24 h (n = 17)]. Patients reached significant clinical improvement (-27% on the Unified Parkinson's Disease Rating Scale part III) and did not show significant differences in cardiovascular tests compared to baseline data. However, an unexpected trend towards increasing systolic blood pressure after head-up tilt test was detected. Our study demonstrates that rotigotine does not influence cardiovascular autonomic responses in early de novo PD patients. Consequently, it may represent a well-tolerated and efficacious therapeutic option in newly diagnosed PD subjects.

Original languageEnglish
Pages (from-to)187-192
Number of pages6
JournalEuropean Neurology
Volume68
Issue number3
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Parkinson Disease
Primary Dysautonomias
Blood Pressure
Antiparkinson Agents
Autonomic Nervous System
Dopamine Agonists
Head
N 0437
Therapeutics
Pharmaceutical Preparations

Keywords

  • Autonomic function tests
  • Dopamine agonists
  • Orthostatic hypotension
  • Parkinson's disease
  • Rotigotine

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Rocchi, C., Pierantozzi, M., Pisani, V., Marfia, G. A., Di Giorgio, A., Stanzione, P., ... Stefani, A. (2012). The impact of rotigotine on cardiovascular autonomic function in early parkinson's disease. European Neurology, 68(3), 187-192. https://doi.org/10.1159/000339000

The impact of rotigotine on cardiovascular autonomic function in early parkinson's disease. / Rocchi, Camilla; Pierantozzi, Mariangela; Pisani, Valerio; Marfia, Girolama Alessandra; Di Giorgio, Alessandra; Stanzione, Paolo; Bernardi, Giorgio; Stefani, Alessandro.

In: European Neurology, Vol. 68, No. 3, 09.2012, p. 187-192.

Research output: Contribution to journalArticle

Rocchi, C, Pierantozzi, M, Pisani, V, Marfia, GA, Di Giorgio, A, Stanzione, P, Bernardi, G & Stefani, A 2012, 'The impact of rotigotine on cardiovascular autonomic function in early parkinson's disease', European Neurology, vol. 68, no. 3, pp. 187-192. https://doi.org/10.1159/000339000
Rocchi, Camilla ; Pierantozzi, Mariangela ; Pisani, Valerio ; Marfia, Girolama Alessandra ; Di Giorgio, Alessandra ; Stanzione, Paolo ; Bernardi, Giorgio ; Stefani, Alessandro. / The impact of rotigotine on cardiovascular autonomic function in early parkinson's disease. In: European Neurology. 2012 ; Vol. 68, No. 3. pp. 187-192.
@article{f10f26fc230242759ccba97d14cfe222,
title = "The impact of rotigotine on cardiovascular autonomic function in early parkinson's disease",
abstract = "Dysautonomia can occur in early stages of Parkinson's disease (PD) influencing tolerance to dopaminergic therapies. Rotigotine, a non-ergot dopamine agonist, has recently been developed as an effective alternative antiparkinsonian drug, but its influence on the autonomic nervous system was not investigated. Twenty subjects out of 34 consecutive de novo PD patients were submitted to full assessment of cardiovascular autonomic function before and after reaching a stable rotigotine regimen [6 mg/24 h (n = 3) or 8 mg/24 h (n = 17)]. Patients reached significant clinical improvement (-27{\%} on the Unified Parkinson's Disease Rating Scale part III) and did not show significant differences in cardiovascular tests compared to baseline data. However, an unexpected trend towards increasing systolic blood pressure after head-up tilt test was detected. Our study demonstrates that rotigotine does not influence cardiovascular autonomic responses in early de novo PD patients. Consequently, it may represent a well-tolerated and efficacious therapeutic option in newly diagnosed PD subjects.",
keywords = "Autonomic function tests, Dopamine agonists, Orthostatic hypotension, Parkinson's disease, Rotigotine",
author = "Camilla Rocchi and Mariangela Pierantozzi and Valerio Pisani and Marfia, {Girolama Alessandra} and {Di Giorgio}, Alessandra and Paolo Stanzione and Giorgio Bernardi and Alessandro Stefani",
year = "2012",
month = "9",
doi = "10.1159/000339000",
language = "English",
volume = "68",
pages = "187--192",
journal = "European Neurology",
issn = "0014-3022",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - The impact of rotigotine on cardiovascular autonomic function in early parkinson's disease

AU - Rocchi, Camilla

AU - Pierantozzi, Mariangela

AU - Pisani, Valerio

AU - Marfia, Girolama Alessandra

AU - Di Giorgio, Alessandra

AU - Stanzione, Paolo

AU - Bernardi, Giorgio

AU - Stefani, Alessandro

PY - 2012/9

Y1 - 2012/9

N2 - Dysautonomia can occur in early stages of Parkinson's disease (PD) influencing tolerance to dopaminergic therapies. Rotigotine, a non-ergot dopamine agonist, has recently been developed as an effective alternative antiparkinsonian drug, but its influence on the autonomic nervous system was not investigated. Twenty subjects out of 34 consecutive de novo PD patients were submitted to full assessment of cardiovascular autonomic function before and after reaching a stable rotigotine regimen [6 mg/24 h (n = 3) or 8 mg/24 h (n = 17)]. Patients reached significant clinical improvement (-27% on the Unified Parkinson's Disease Rating Scale part III) and did not show significant differences in cardiovascular tests compared to baseline data. However, an unexpected trend towards increasing systolic blood pressure after head-up tilt test was detected. Our study demonstrates that rotigotine does not influence cardiovascular autonomic responses in early de novo PD patients. Consequently, it may represent a well-tolerated and efficacious therapeutic option in newly diagnosed PD subjects.

AB - Dysautonomia can occur in early stages of Parkinson's disease (PD) influencing tolerance to dopaminergic therapies. Rotigotine, a non-ergot dopamine agonist, has recently been developed as an effective alternative antiparkinsonian drug, but its influence on the autonomic nervous system was not investigated. Twenty subjects out of 34 consecutive de novo PD patients were submitted to full assessment of cardiovascular autonomic function before and after reaching a stable rotigotine regimen [6 mg/24 h (n = 3) or 8 mg/24 h (n = 17)]. Patients reached significant clinical improvement (-27% on the Unified Parkinson's Disease Rating Scale part III) and did not show significant differences in cardiovascular tests compared to baseline data. However, an unexpected trend towards increasing systolic blood pressure after head-up tilt test was detected. Our study demonstrates that rotigotine does not influence cardiovascular autonomic responses in early de novo PD patients. Consequently, it may represent a well-tolerated and efficacious therapeutic option in newly diagnosed PD subjects.

KW - Autonomic function tests

KW - Dopamine agonists

KW - Orthostatic hypotension

KW - Parkinson's disease

KW - Rotigotine

UR - http://www.scopus.com/inward/record.url?scp=84865586582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865586582&partnerID=8YFLogxK

U2 - 10.1159/000339000

DO - 10.1159/000339000

M3 - Article

C2 - 22948481

AN - SCOPUS:84865586582

VL - 68

SP - 187

EP - 192

JO - European Neurology

JF - European Neurology

SN - 0014-3022

IS - 3

ER -